Skip to main content
. 2020 Nov 16;130(12):6739–6753. doi: 10.1172/JCI139681

Figure 5. Clinical studies of MVT-602 in women with oligo/anovulatory disorders.

Figure 5

(A) Mean (± SEM) plasma concentration of MVT-602 (pmol/L) versus time (hours) in women receiving an s.c. bolus of 0.03 nmol/kg of MVT-602. Healthy women in the follicular phase are presented in black (n = 9), women with PCOS in green (n = 6), and women with HA in blue (n = 6). No significant difference was detected by 2-way ANOVA. (B, D, and E) Mean (± SEM) change from baseline levels in serum LH (IU/L) (B), serum FSH (IU/L) (D), and serum estradiol (pmol/L) (E) in healthy women (black; n = 9), women with PCOS (green; n = 6), and women with HA (blue; n = 6) after receiving a single s.c. bolus of 0.03 nmol/kg MVT-602. Groups were compared by 2-way ANOVA. *P = 0.025 for LH, *P = 0.001 for FSH; *P = 0.02 for estradiol. (C) Median (IQR) of modeled values of AUC of serum LH (IU∙h/L) with 0.03 nmol/kg MVT-602 in women in the healthy follicular phase, women with PCOS, and women with HA. No significant difference was detected by Kruskal-Wallis test.